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Abstract
Introduction:  Squamous  cell  carcinoma  is  the  most  common  neoplasm  of  the  larynx,  and  its
evolution  depends  on  tumor  staging.  Vascular  endothelial  growth  factor  is  a  marker  of  angio-
genesis, and  its  expression  may  be  related  to  increased  tumor  aggressiveness,  as  evidenced  by
the presence  of  cervical  lymphatic  metastases.
Objectives:  To  evaluate  the  expression  of  the  vascular  endothelial  growth  factor  marker  in
non-glottic  advanced  squamous  cell  carcinoma  of  the  larynx  (T3/T4)  and  correlate  it  with  the
presence  of  cervical  lymph  node  metastases.
Methods:  Retrospective  clinical  study  and  immunohistochemical  analysis  of  vascular  endothe-
lial growth  factor  through  the  German  scale  of  immunoreactivity  in  products  of  non-glottic
squamous  cell  carcinomas.
Results:  This  study  analyzed  15  cases  of  advanced  non-glottic  laryngeal  tumors  (T3/T4),  four
of which  exhibited  cervical  lymphatic  metastases.  There  was  no  correlation  between  vascular
endothelial  growth  factor  expression  and  the  presence  of  cervical  metastases.
Conclusion:  Although  vascular  endothelial  growth  factor  was  expressed  in  a  few  cases,  there
was no  correlation  with  the  spread  of  cervical  lymph  metastases.
© 2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
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Correlac¸ão  entre  expressão  do  fator  de  crescimento  endotelial  e  presenc¸a  de
metástase  linfática  nos  carcinomas  epidermoides  avanc¸ados  de  laringe
Resumo
Introduc¸ão:  O  carcinoma  de  células  escamosas  é  a  neoplasia  mais  frequente  da  laringe  e  seu
prognóstico  depende  do  estadiamento.  A  progressão  da  doenc¸a  está  relacionada  a  fatores
intrínsecos  celulares  do  câncer,  não  conhecidos.  O  VEGF  (vascular  endothelial  growth  factor)  é
um marcador  de  angiogênese  e  sua  expressão  pode  estar  relacionada  a  uma  maior  agressividade
tumoral, evidenciada  pela  presenc¸a  de  metástases  linfáticas  cervicais.
Objetivos:  Avaliar  a  expressão  do  marcador  VEGF  em  carcinoma  de  células  escamosas  da  laringe
avanc¸ados (T3/T4),  não  glóticos  e  correlacionar  quanto  à  presenc¸a  de  metástases  linfáticas
cervicais.
Método: Estudo  clínico  retrospectivo  de  análise  imunohistoquimica  do  VEGF  através  da  escala
Germânica  de  imunorreatividade  em  produtos  de  carcinomas  epidermóides  não  glóticos.
Resultados:  Analisados  15  casos  de  tumores  avanc¸ados  de  laringe  (T3/T4)  não  glóticos,  sendo
sete com  presenc¸a  de  metástases  linfáticas  cervicais.  Não  houve  correlac¸ão  entre  a  expressão
do VEGF  e  a  presenc¸a  de  metástases  cervicais.
Conclusão:  O  VEGF  foi  pouco  expressado  nos  casos  estudados  e  não  foi  observada  sua  correlac¸ão
com a  disseminac¸ão  de  metástase  linfática  cervical.
© 2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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Angiogenesis  is  characterized  by  the  formation  of  new
capillary  blood  vessels  that  originate  from  a  pre-existing
vasculature.  This  process  is  essential  to  provide  nutrients,
oxygen,  and  growth  factors  that  support  cell  function  and
survival.  Therefore,  it  is  associated  with  tumor  growth  and
metastasis.1,2
A  complex  interaction  between  endothelial  cells,  extra-
cellular  protein  matrix,  and  soluble  factors  in  plasma  occurs
in  angiogenesis.  Endothelial  cells  leave  their  quiescent  state
when  stimulated  by  VEGF  (vascular  endothelial  growth  fac-
tor)  and  initiate  the  following  steps:  dissolution  of  the  basal
membrane;  migration  and  proliferation  of  endothelial  cells;
capillary  tube  formation;  and  maturation  and  survival  of
newly  formed  vessels.  This  ensures  the  required  blood  sup-
ply  for  neoplastic  evolution.1,2
Squamous  cell  carcinoma  is  the  most  common  neoplasm
of  the  larynx  and  its  prognosis  depends  on  the  size  of  the
lesion,  the  level  of  local  invasion,  cervical  lymphatic  spread,
and  presence  of  distant  metastases.1,3
Histologically,  squamous  cell  carcinoma  of  the  larynx  and
hypopharynx  are  similar  to  that  of  other  regions  and  are
classiﬁed  into  different  degrees  of  differentiation  by  the
neoplastic  proliferation  of  squamous  cells  and  the  nature
of  tumor  inﬁltration.  Depending  on  the  degree  of  kera-
tinization  and  cellular  atypia,  they  are  classiﬁed  as  well,
moderately,  or  poorly  differentiated.3
Lymphatic  drainage  of  the  glottic  region  is  scarce;  this
decreases  the  metastatic  potential  of  tumors  that  develop  in
this  region.  The  supraglottic  and  subglottic  regions  have  rich
lymphatic  drainage,  with  the  supraglottic  region  draining
mainly  into  the  upper  jugulocarotid  chain  lymph  nodes  and
to  a  lesser  degree  into  the  middle  jugulocarotid  chain  lymph
M
T
sodes  whereas  the  subglottic  region  tends  to  drain  ipsilat-
rally  to  the  middle  and  lower  jugulocarotid  lymph  nodes,
hat  may  drain  to  the  anterosuperior  mediastinal  chain.3 For
his  reason,  we  decided  to  exclude  glottal  tumors  from  the
tudy.
The  literature  discussing  treatment  of  these  tumors  has
ncreased  and  studies  of  new  chemotherapeutic  agents  and
argeted  therapies  have  gained  prominence.  Examples  of
his  include  the  promising  results  reported  for  cetuximab,
 monoclonal  antibody  that  blocks  endothelial  growth  fac-
or  receptor  (EGFR)  used  for  the  treatment  of  head  and  neck
ancer,  and  bevacizumab  and  other  recombinant  anti-VEGF
onoclonal  antibodies.4,5
These  antibodies  bind  to  VEGF  isoforms  with  high  afﬁnity
nd  prevent  the  cytokine  from  binding  with  the  endothelial
ell  receptor  and  triggering  the  angiogenesis  process.  The
se  of  angiogenesis-inhibiting  monoclonal  antibodies  for  the
reatment  of  colorectal,  kidney,  and  lung  cancer  has  already
een  approved  by  the  FDA.  For  the  treatment  of  larynx/head
nd  neck  cancer,  they  are  still  being  assessed.4,5
Considering  that  VEGF  plays  an  important  role  in  tumor
ngiogenesis  and  that  this  factor  is  associated  with  tumor
ormation,  progression,  and  metastasis,  its  expression  could
e  related  to  increased  tumor  aggressiveness  evidenced  by
ervical  metastatic  spread.2
The  present  study  aimed  to  evaluate  the  expression  of
EGF  marker  in  advanced,  non-glottic  squamous  cell  car-
inoma  of  the  larynx  (T3/T4)  and  correlate  it  with  the
resence  or  absence  of  cervical  lymph  node  metastasis.ethods
his  was  a  retrospective  clinical  study,  conducted  in  a
ample  obtained  by  a  cross-section  design  in  a  historical
6 Bonhin  RG  et  al.
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Table  1  Distribution  of  15  patients  according  to  TNM
staging.
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ohort,  using  materials  (surgical  specimens)  obtained  from
he  resection  of  non-glottic  squamous  cell  carcinoma  of  the
arynx  from  surgeries  in  a  tertiary  university  hospital  during
 speciﬁed  period  of  ten  years.  The  procedures  performed
ith  the  patients  were  hemi-laryngectomy  or  total  laryngec-
omy,  with  respective  lymphadenectomy.
Patients  were  divided  by  the  presence  or  absence
f  metastases  and  by  surgical-clinical  staging.  Cases  of
on-glottic  squamous  cell  carcinoma  of  the  larynx  and
ypopharynx  were  obtained  from  the  tumor  bank  of  the
athological  Anatomy  Department  of  a  tertiary  hospital.  Of
hese,  15  cases  of  advanced  non-glottic  larynx  tumors  were
elected,  as  well  as  three  cases  of  tumors  of  the  base  of  the
ongue,  ten  cases  of  supraglottic  tumors,  and  two  cases  of
ypopharynx/pyriform  sinus  tumors.
nclusion  and  exclusion  criteria
umors  whose  parafﬁn  blocks  were  located  and  contained
nough  material  for  new  sections  were  included  in  the
urvey.  We  required  adequate  tissue  and  data  for  stag-
ng  each  lesion  by  its  tumor  location,  and  determining
esion  size,  level  of  invasion  into  adjacent  tissues,  lymph
ode  involvement,  and  distant  metastasis.  Clinical  data  and
umor  staging  were  obtained  from  patients’  records.
All  cases  that  were  not  in  accordance  with  the  above-
entioned  criteria  were  excluded.
mmunohistochemical  analysis
mmunohistochemical  analysis  was  carried  out  using  the
vidin-biotin-peroxidase  method  and  the  VEGF  antibody
type  IgG1,  1:100  dilution,  Santa  Cruz,  pretreated  with
itrate  buffer).
Positive  and  negative  marker  controls  were  prepared  in
rder  to  compare  with  the  studied  cases.  Lymphoid  tissue
as  used  as  positive  control  (as  per  manufacturer’s  instruc-
ions).
Slide  reading  was  carried  out  randomly,  by  an  investigator
ho  neither  had  knowledge  of  the  previous  diagnosis  given
y  the  pathologist  nor  knowledge  of  the  patient’s  clinical
tatus,  by  comparing  the  slides  with  positive  and  negative
ontrols.  Scanned  photographs  at  high  magniﬁcation  (400×)
ere  made  of  highly  reactive  areas  (hot  spots),  using  a
ikon  COOLPIX  Camera  995.  After  that,  the  images  were
ent  to  the  computer  for  histological  analysis,  which  used
he  Imagelab  2000  software.
All  parameters  were  evaluated  in  a  blinded  manner.
Finally,  the  histological  and  immunohistochemical  ﬁnd-
ngs  were  correlated  with  the  TNM  stage  (TNM-UICC-AJCC
lassiﬁcation  [2010]).6
The  degree  of  VEGF  expression  was  based  on  the  German
cale  of  immunoreactivity.  This  consists  in  multiplying  the
oefﬁcient  of  the  immunomarker  expression  intensity  by  the
ercentage  coefﬁcient  of  positive  cells.
The  coefﬁcient  of  the  immunomarker  expression  inten-
ity  was  graded  from  0  to  3,  thus  characterized:  0,  no
taining;  1,  stained  weakly;  2,  stained  moderately;  3,
tained  strongly.
To  obtain  the  percentage  coefﬁcient  of  positive  cells,  the
ollowing  sequence  was  used:  coefﬁcient,  represented  by
c
s
2N1/N2/N3  2  2
he  number  of  positive  (stained)  and  negative  (not  stained)
ells,  was  counted  on  a  sample  space  of  at  least  500  cells,
nd  stratiﬁed  as  follows:  coefﬁcient  of  0  if  there  was  no
taining;  coefﬁcient  of  1  if  there  was  1--10%  positivity;  coef-
cient  of  2  if  there  was  11--50%  positivity;  coefﬁcient  of  3
f  there  was  51--80%  positivity;  and  coefﬁcient  of  4  if  there
as  81--100%  positivity.
The  ﬁnal  value  of  the  German  scale  of  immunore-
ctivity  (coefﬁcient  of  the  immunomarker  expression
ntensity  ×  coefﬁcient  of  positive  cell  percentage)  ranged
rom  0  to  12,  stratiﬁed  as:  0  (negative),  1--4  (poor),  5--8
moderate),  and  9--12  (strong).  To  facilitate  the  analysis,
he  negative/weak  cases  were  considered  as  group  1  and
he  moderate/strong  cases  as  group  2.
tatistical  analysis
fter  pooling  the  data,  statistical  analyses  were  performed
sing  the  IBM  software  SPSS  Statistics®,  using  the  chi-
quared  test  and  Fisher’s  exact  test.
To  simplify  and  better  analyze  the  data,  they  were
rouped  as  follows:
 German  Scale  of  Immunoreactivity:
Negative  and  weak  --  Group  1
Moderate  and  strong  --  Group  2
 Cell  proliferation  index:
Low  and  slight  cell  proliferation  --  Group  1
Moderate  and  high  cell  proliferation  --  Group  2
 TNM  (TNM-UICC-AJCC  Classiﬁcation--2010)6
T1  and  T2  --  Group  1/T3  and  T4  --  Group  2
N0  --  Group  0/N1,  N2,  and  N3  --  Group  1
thical  aspects
he  study  was  approved  by  the  Ethics  Committee  of  the
nstitution  (485/11).
esults
 total  of  15  cases  were  evaluated,  including  four  with  cer-
ical  metastases.
The  staging  of  these  tumors,  deﬁned  through  TNM  (2010),
s  described  in  Table  1.  It  can  be  observed  that  only  four  of
he  15  cases  had  cervical  metastases.  Table  1  further  details
he  distribution  of  the  four  cases  with  cervical  metastasis
ccording  to  the  T  classiﬁcation.Table  2  shows  the  expression  of  VEGF  in  the  studied
ases,  considering  cases  that  had  negative  or  weak  expres-
ion  as  group  1,  and  moderate  or  strong  expression  as  group
 according  to  the  German  scale.  Overexpression  of  VEGF
Evaluate  the  expression  of  VEGF  marker  in  non-glottic  squamous
Table  2  Distribution  of  groups  1  and  2  (VEGF  expression)
in 15  cases,  their  correlation  with  the  presence  of  cervical
metastases,  and  statistical  analysis.
n  N0  N1/N2/N3
Group  1
(negative/weak
expression  VEGF)
11  7  4
Group 2
(moderate/strong
expression  VEGF)
4  4  0
VEGF vs.  N0  or  N1/N2/N3
Chi-squared  test 0.159
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VEGF, vascular endothelial growth factor.
in  epithelial  cells  of  squamous  carcinomas  was  observed  in
only  26.6%  of  the  cases  studied.
Table  2  also  shows  the  correlation  of  VEGF  expression  in
groups  1  and  2,  according  to  the  presence  or  absence  of
cervical  lymph  node  metastasis,  with  p  =  0.363.
There  was  no  correlation  between  the  overexpression
of  this  marker  with  the  presence  of  cervical  lymph  node
metastasis  (p  =  0.159).
Discussion
In  the  literature,  studies  evaluating  head  and  neck  tumors,
which  include  not  only  squamous  cell  carcinomas  of
the  larynx  (glottic  and  non-glottic),  but  also  oral  cavity
and  pharynx  tumors,  have  reported  an  increase  in  VEGF
correlated  with  increased  angiogenesis,  with  neoplastic  pro-
gression,  and  with  prognosis;  the  analyses  took  into  account
the  positivity  of  the  marker,  regardless  of  its  intensity.1,2,7--9
There  is  only  one  recent  study  that  speciﬁcally  addressed
laryngeal  cancer  and  its  association  with  VEGF.  In  this  case,
the  positivity  of  this  marker  was  higher  than  72%,10 unlike
the  results  found  here,  perhaps  due  to  the  small  number  of
cases  in  the  present  sample.
There  is  divergence  among  authors  regarding  the  corre-
lation  between  VEGF  expression  and  the  presence  of  lymph
node  and  distant  metastases.  Some  authors  found  positive
results  between  VEGF  expression  and  the  presence  of  cervi-
cal  lymph  node  metastases  and  distant  metastases.2,8,9,11
The  meta-analysis  by  Panayiotis  et  al.  found  that  VEGF
correlates  with  poor  survival  in  patients  with  head  and
neck  squamous  cell  carcinoma;  however,  the  correlation
of  VEGF  overexpression  with  the  presence  of  lymph  node
metastasis/distant  metastasis  is  yet  to  be  established.12
Boonkitticharoen  also  found  no  correlation  between  this
marker  and  metastases.13
A  recent  Asian  study  reported  a  close  association
between  VEGF-C/VEGFR-3  expression  and  lymph  node
metastases  in  squamous  cell  carcinomas  of  the  larynx.  The
expression  of  these  markers  was  positive  only  in  the  analy-
sis  of  cervical  metastases,  and  did  not  correlate  with  age,
gender,  T  stage,  or  primary  location  of  the  laryngeal  lesion.14
The  antibody  against  epithelial  growth  factor  receptor
(EGFR)  has  already  been  approved  by  the  FDA  (Food  and
Drugs  Administration)  for  a  few  years  for  the  treatment  of cell  carcinoma  61
ead  and  neck  carcinoma.  However,  its  use  in  patients  with
umor  recurrence  and/or  metastatic  disease  has  shown  little
fﬁcacy.  VEGF  has  been  implicated  as  a  potential  mechanism
f  resistance  to  anti-EGFR  therapy.  Therefore,  recent  clini-
al  trials  seek  the  use  of  anti-EGFR  drugs  in  combination  with
nti-VEGF  antibodies  (bevacizumab),  a  combination  that  has
een  well  tolerated  by  patients  (Phase  I/II  studies).15--17
Currently,  several  phase  II  clinical  trials  have  stud-
ed  the  role  of  bevacizumab  in  tumors  of  the  head  and
eck,  including  its  combination  with  cetuximab,  cisplatin,
nd  radiotherapy  for  non-metastatic  stage  III/IV  cancer;
ith  erlotinib  in  locoregional  advanced  and/or  metastatic
isease;  and  with  cetuximab,  docetaxel,  and  cisplatin
induction)  followed  by  cetuximab,  cisplatin,  and  radio-
herapy  in  previously  untreated  locoregional  advanced
isease.18
The  emergence  of  this  promising  treatment  raises  impor-
ant  issues.  With  broad  indications,  the  indiscriminate  use
f  bevacizumab  can  develop  resistance.  Therefore,  stud-
es  have  sought  to  deﬁne  and  validate  biomarkers  of  its
fﬁciency.  Until  then,  speciﬁc  VEGF  genotypes  and  arte-
ial  hypertension  (induced  or  aggravated  by  the  treatment)
ppear  to  be  related  to  a  better  response.19 Other  markers
uch  as  CD105,  CD34,  and  CD31,  related  to  the  process  of
ngiogenesis,  may  be  useful  in  the  identiﬁcation  of  patients
ho  are  candidates  for  more  aggressive  anti-neoplastic  ther-
py,  including  the  use  of  monoclonal  antibodies.20
Some  authors  believe  that  the  regulation  of  VEGF  expres-
ion  can  be  modulated  by  the  microRNA-206,  and  this
athway  can  be  used  in  the  future  for  anticancer  therapy
elated  to  this  tumor  marker.21
Although  this  study  did  not  observe  a  correlation  of  VEGF
ith  cervical  lymph  node  metastasis,  the  targeted  therapy
as  shown  promising  results  for  the  treatment  of  head  and
eck  cancer.22
onclusion
EGF  was  scarcely  expressed,  and  no  correlation  with  cer-
ical  lymph  metastasis  spread  was  observed  in  this  sample
f  15  cases.
onﬂicts of interest
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